![Murray Stewart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Murray Stewart
Directeur/Bestuurslid bij X4 PHARMACEUTICALS, INC.
Vermogen: 193 419 $ op 31-05-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Paula Ragan | M | 54 | 10 jaar | |
Paul Carter | M | 63 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 14 jaar |
Mark Dipaolo | M | 53 | 3 jaar | |
Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 jaar |
Stephen P. Squinto | M | 67 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 jaar |
Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 jaar |
Odysseas Kostas | M | 49 | 1 jaar | |
Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 jaar |
Phil Thomson | M | - | 13 jaar | |
Luca Santarelli | M | 55 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 jaar |
Emma Walmsley | F | 55 | 14 jaar | |
Thomas Woiwode | M | 52 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 jaar |
Adam Mostafa | M | 44 | 6 jaar | |
Mary DiBiase | M | 63 | 7 jaar | |
David Connolly | M | - | 5 jaar | |
Jesse Goodman | M | 72 | 8 jaar | |
Keith Horn | M | 66 | 1 jaar | |
Patrice Bonfiglio | F | 40 | 1 jaar | |
Tony Wood | M | - | 7 jaar | |
Diane Sullivan | F | 62 | 1 jaar | |
Françoise de Craecker | F | 62 | 3 jaar | |
Michael Wyzga | M | 69 | 6 jaar | |
Stuart Arbuckle | M | 58 | 5 jaar | |
Paul Cohen | M | 49 | 1 jaar | |
Jennifer Good | F | 59 | 5 jaar | |
David McGirr | M | 69 | 7 jaar | |
Camille Bedrosian | M | 71 | 4 jaar | |
Lynn Tetrault | F | 61 | 4 jaar | |
Louis Sterling | M | 45 | 1 jaar | |
Bill Aliski | M | 75 | 5 jaar | |
Alison Lawton | F | 62 | 4 jaar | |
Gary Bridger | M | 61 | 6 jaar | |
Timothy Woodthorpe | M | - | 24 jaar | |
Pamela Cramer | F | 50 | 3 jaar | |
Jim Flaherty | M | - | 5 jaar | |
Frannie DeFranco | F | - | 14 jaar | |
Anita Kidgell | F | - | 16 jaar | |
Sally Jackson | F | - | 23 jaar | |
Elisabeth Crönert-Bendell | M | - | 3 jaar | |
Joseph Shulman | M | 49 | 4 jaar | |
Mark Baldry | M | 60 | 2 jaar | |
Diana Conrad | F | - | 8 jaar | |
Yann Mazabraud | M | 51 | 4 jaar | |
R. Woods | M | 56 | 1 jaar | |
Christophe Arbet-Engels | M | - | 1 jaar | |
María Cristina de Luna Basagoiti | F | - | 14 jaar | |
Luke Miels | M | - | 7 jaar | |
Art Taveras | M | 60 | 4 jaar | |
Victoria Whyte | F | - | 15 jaar | |
Christian Meyer | M | 56 |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
Jennifer Chien | F | 49 | 4 jaar | |
Barbara Beirer | M | - |
Vivli Center For Global Clinical Research Data
| - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 46 | 46.00% |
Verenigde Staten | 29 | 29.00% |
Ierland | 12 | 12.00% |
Zwitserland | 11 | 11.00% |
Canada | 4 | 4.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Murray Stewart
- Persoonlijk netwerk